Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evofem Biosciences, Inc.EVFM · Entity 8607 | Director | May 12, 2021 | May 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evofem Biosciences, Inc.
Report date May 12, 2021 · Filed May 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2031-05-12 | Direct | 90,000 |
Reported balance
After 2021-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-12 · Grant · Acquired 90,000 · Balance 90,000 F1: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Dr. Hall's board and committee services. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Dr. Hall's board and committee services.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2021 Filed May 13, 2021 16:13 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001618835-21-000108 · wf-form4_162093677602785.xml · derivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Dr. Hall's board and committee services. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:38 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 5,000 | $2.85 | $14,250.00 |
DisclosureSEC source: 0001618835-20-000198 · wf-form4_159244068645749.xml · nonDerivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 16:29 UTC Amendment | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 5,000 | $2.85 | $14,250.00 |
DisclosureSEC source: 0001618835-20-000203 · wf-form4a_159251215883461.xml · nonDerivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The original Form 4, filed on June 17,2020, is being amended to update the price range reported in Column 4 of Table I. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.845 to $2.85, inclusive. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| May 12, 2020 Filed May 13, 2020 16:39 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001618835-20-000133 · wf-form4_158940232263709.xml · derivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2020. The option was awarded in connection with Dr. Hall's board and committee services. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:02 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.05 | $0.00 |
DisclosureSEC source: 0001618835-19-000105 · wf-form4_155985132048062.xml · derivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of June 5, 2019. The option was awarded in connection with Dr. Hall's board and committee services. Read SEC document |
| May 08, 2018 Filed May 9, 2018 18:21 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 12,875 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001618835-18-000014 · wf-form4_152590442736853.xml · derivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Underlying: Common Stock · 12,875 shares Expires 2028-05-08 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 8, 2018. The option was awarded in connection with Dr. Hall's board and committee services. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 18:13 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 24,691 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019667 · doc4.xml · derivative · entry 1 Hall William Walmsley · CIK 0001726731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,691 Underlying: Common Stock · 24,691 shares Expires 2028-03-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Dr. Hall's board and committee services. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.